98. 好酸球性消化管疾患 Eosinophilic gastrointestinal disease Clinical trials / Disease details


臨床試験数 : 171 薬物数 : 184 - (DrugBank : 47) / 標的遺伝子数 : 42 - 標的パスウェイ数 : 141

  
7 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04856891
(ClinicalTrials.gov)
May 20, 202120/4/2021A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic DuodenitisA Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AK002 in Patients With Moderately to Severely Active Eosinophilic Duodenitis Who Have an Inadequate Response With, Lost Response to, or Were Intolerant to Standard TherapiesEosinophilic Duodenitis;Eosinophilic GastroenteritisDrug: AK002;Other: PlaceboAllakos, Inc.NULLActive, not recruiting18 Years80 YearsAll94Phase 3United States
2NCT04620811
(ClinicalTrials.gov)
December 3, 20203/11/2020An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)A Phase 3, Multicenter, Open-Label, Extension Study to Evaluate the Efficacy and Safety of AK002 in Patients That Were Previously Enrolled in AK002-016 or AK002-012 Studies and Have Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)Eosinophilic Gastritis;Eosinophilic DuodenitisDrug: lirentelimabAllakos, Inc.NULLEnrolling by invitation18 Years80 YearsAll170Phase 3United States
3EUCTR2019-004391-19-NL
(EUCTR)
30/07/202013/05/2020Study to Evaluate the Efficacy and Safety of AK002 in Subjects with Active Eosinophilic EsophagitisA Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safetyof AK002 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis Active Eosinophilic Esophagitis (EoE)
MedDRA version: 20.1;Level: PT;Classification code 10064212;Term: Eosinophilic oesophagitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Code: AK002
INN or Proposed INN: not available
Allakos Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
300Phase 2;Phase 3United States;Australia;Netherlands
4NCT04322708
(ClinicalTrials.gov)
July 6, 202024/3/2020A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic EsophagitisA Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lirentelimab (AK002) in Adult and Adolescent Patients With Active Eosinophilic EsophagitisEosinophilic EsophagitisOther: Placebo;Drug: lirentelimab (AK002)Allakos, Inc.NULLActive, not recruiting12 Years80 YearsAll277Phase 2/Phase 3United States;Australia;Netherlands
5NCT04322604
(ClinicalTrials.gov)
June 18, 202024/3/2020A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AK002 in Patients With Moderately to Severely Active Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)Eosinophilic Gastritis;Eosinophilic DuodenitisDrug: lirentelimab (AK002);Other: PlaceboAllakos, Inc.NULLActive, not recruiting18 Years80 YearsAll180Phase 3United States
6NCT03664960
(ClinicalTrials.gov)
November 14, 20186/9/2018An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic DuodenitisA Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Safety and Tolerability of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)Eosinophilic Gastritis;Eosinophilic Gastroenteritis;Eosinophilic DuodenitisDrug: AK002Allakos, Inc.NULLActive, not recruiting18 Years80 YearsAll58Phase 2United States
7NCT03496571
(ClinicalTrials.gov)
July 18, 20186/4/2018A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic GastroenteritisA Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamic Effect of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic GastroenteritisEosinophilic Gastritis;Eosinophilic GastroenteritisDrug: AK002;Other: PlaceboAllakos, Inc.NULLCompleted18 Years80 YearsAll65Phase 2United States